Article

43 views
A unicorn is a startup company with a current valuation of US$1 billion or more. Medgenera DATALABS has already compiled 25 venture-backed private healthcare companies with post-money valuations of US $1 billion or more. It will also release the “Healthcare Unicorn Startups Live Database” on 20th February 2018 in the resource centre category. The live database will track the analytics of global healthcare startups in real-time and update accordingly. The resource will be accessible to all the subscribers of MEDGENERA ALL-ACCESS. 
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

A unicorn is a startup company with a current valuation of US$1 billion or more. Aileen Lee, the American venture ...

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

More in MEDGENERA ORIGINAL


MEDGENERA ORIGINAL

Drugs in Clinical Trials Database

The live database provides the detailed information about the experimental drugs ongoing the clinical trials in different countries. It also tracks the clinical trials in real-time and updates the status accordingly. The resource can be accessible to all the subscribers of MEDGENERA ALL-ACCESS.

MEDGENERA ORIGINAL

FDA-Approved Drugs Database

The live database provides the detailed information about the drugs approved by the Food and Drug Administration (FDA or USFDA) from January 2010 and till date. It also tracks the clinical trials in real-time and updates the approval of the new drugs accordingly. The resource will be accessible to all the subscribers of MEDGENERA ALL-ACCESS.

MEDGENERA ORIGINAL

Global Digital Healthcare Investors Database

The live 'Global Digital Healthcare Investors Database' provides the detailed information about the active digital healthcare investors from around the world and also track the analytics of global digital healthcare investments in real-time and update accordingly. The resource can be accessible to all the subscribers of MEDGENERA ALL-ACCESS.

MEDGENERA ORIGINAL

Healthcare Unicorn Startups

A unicorn is a startup company with a current valuation of US$1 billion or more. Medgenera DATALABS has already compiled 25 venture-backed private healthcare companies with post-money valuations of US $1 billion or more. It will also release the “Healthcare Unicorn Startups Live Database” on 20th February 2018 in the resource centre category. The live database will track the analytics of global healthcare startups in real-time and update accordingly. The resource will be accessible to all the subscribers of MEDGENERA ALL-ACCESS. 

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Healthcare in India is showing a gradual progress and there is an abundance of opportunity to create an evolving business by tackling the major challenges of the mass population. Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our observations of the current Indian market, its behavior, challenges, and opportunities.

MARKET INSIGHTS

9 Most Valuable Drugs Under Development (2018)

The top 9 drugs currently under research and developments are ranked based on their Net Present Value. These drugs are forecasted to be the future blockbuster. With $10,199 million Net Present Value, Aducanumab, the Ant-Alzheimer's investigational drug of Biogen is ranked as the topmost valued upcoming drug under development. Total Word Counts of the article: 782. Continue reading..